Filing Flows › Aytu Biopharma (AYTU) › Q3 FY26 › vs Q3 FY25
Aytu Biopharma (AYTU) Q3 FY26 vs Q3 FY25 (year over year)
Aytu Biopharma's revenue fell $6.0M (-33%) from $18.5M in Q3 FY25 to $12.4M in Q3 FY26.
Aytu Biopharma, Q3 FY26: revenue $12.4M (-33% year over year), operating margin -32.7%, net loss $5.6M, operating cash flow −$4.2M. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $12.4M | $18.5M | −$6.0M | -33% |
| Net loss | $5.6M | −$4.0M | $9.6M | — |
| Costs & expenses | $18.0M | $20.0M | −$2.0M | -10% |
| Operating costs | $16.5M | $16.0M | $444K | +3% |
| Interest & other, net | $1.5M | −$1.5M | $3.0M | — |
| Income tax | $10K | −$122K | $132K | — |
| Cost of revenue | $4.8M | $5.6M | −$834K | -15% |
| Sales & marketing | $5.9M | $5.2M | $735K | +14% |
| General & admin | $5.0M | $4.1M | $864K | +21% |
| Other operating costs | $761K | $920K | −$159K | -17% |
| Operating cash sources | $5.6M | −$4.0M | $9.6M | — |
| Depreciation & amortization | $1.1M | $1.3M | −$166K | -13% |
| Share-based compensation | $148K | $139K | $9K | +6% |
| Working capital & other | $167K | −$11.9M | $12.0M | — |
| Cash used in operations | $4.2M | $6.5M | −$2.3M | -35% |
| Net loss absorbed | $5.6M | −$4.0M | $9.6M | — |
Questions
How much did Aytu Biopharma's revenue grow year over year in Q3 FY26?
Aytu Biopharma's revenue fell $6.0M (-33%) from $18.5M in Q3 FY25 to $12.4M in Q3 FY26.